INVESTORS

Press Releases

Year

Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting

May 16, 2022

Multiple Oral Presentations and Posters to Demonstrate Differentiated Attributes of ARCUS® Genome Editing Platform for Efficient Gene Insertion and Gene Knockout New Primary Hyperoxaluria Type 1 (PH1) Preclinical Data Demonstrate a Robust ARCUS Nuclease Optimization Process Leading to 98% Knockdown...

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2022

DURHAM, N.C. --(BUSINESS WIRE)--May 12, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022 , the Compensation Committee of Precision’s...

Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update

May 9, 2022

- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo Gene Editing Data for Primary Hyperoxaluria Type 1 and Chronic Hepatitis B...

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting

May 2, 2022

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS ® gene editing therapies DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ®...

Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022

May 2, 2022

Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

March 15, 2022

- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the American Society of Hematology Meeting Showing High Response Rates to PBCAR0191 in Heavily Treated...

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022

March 8, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and...

Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference

January 4, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that Michael Amoroso , Chief Executive...

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 18 of 18

Investors

Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies